Featured Research

from universities, journals, and other organizations

Study examines effects of delaying treatment for ocular hypertension

Date:
March 8, 2010
Source:
JAMA and Archives Journals
Summary:
Early treatment of ocular hypertension appears to reduce the risk of developing glaucoma, especially in individuals at the highest risk, according to a new study. However, this strategy may not offer an absolute benefit in individuals at low risk.

Early treatment of ocular hypertension appears to reduce the risk of developing glaucoma, especially in individuals at the highest risk, according to a report in the March issue of Archives of Ophthalmology, one of the JAMA/Archives journals. However, this strategy may not offer an absolute benefit in individuals at low risk.

Related Articles


Glaucoma is one of the most common causes of blindness in the United States and worldwide, according to background information in the article. High pressure within the eye -- referred to as elevated intraocular pressure or ocular hypertension -- is a leading risk factor for the development of primary open-angle glaucoma, the most common type. It is also the only risk factor that is modifiable.

"It is estimated that 4 percent to 7 percent of the U.S. population older than 40 years has ocular hypertension," the authors write. "There is substantial controversy on how to manage this large group of individuals who are at higher risk of developing glaucoma than the general population." The Ocular Hypertension Treatment Study previously demonstrated that lowering intraocular pressure in this population could delay or prevent the onset of glaucoma, but the optimal timing for initiating treatment has yet to be determined.

Michael A. Kass, M.D., of Washington University School of Medicine, St. Louis, and colleagues in the Ocular Hypertension Treatment Study Group compared the safety and efficacy of earlier vs. later treatment in preventing glaucoma among 1,636 individuals with elevated intraocular pressure. Participants were randomly assigned to either observation or topical ocular pressure-lowering medication. Those assigned to receive medication were treated for a median (midpoint) time of 13 years, whereas the observation group was monitored for a median time of 7.5 years and then received medication for a median of 5.5 years.

Overall, 22 percent of participants in the original observation group and 16 percent in the original medication group developed glaucoma after 13 years -- meaning early treatment was associated with a 27 percent reduction in the risk of glaucoma. Among the one-third of individuals who had the highest initial risk of developing glaucoma -- as determined by factors such as age, corneal thickness and baseline intraocular pressure -- 40 percent in the observation group and 28 percent in the medication group developed glaucoma. There was little evidence of adverse events associated with the medication.

"The data presented suggest that ocular hypertension patients at high risk may benefit from more frequent examinations and from early treatment, taking into consideration age, health status, life expectancy and the patient preference," the authors write. "Conversely, most ocular hypertension patients at low risk could be followed up at less frequent intervals without treatment. Delaying treatment for 7.5 years in low-risk participants resulted in only a small absolute increase in the overall frequency of primary open-angle glaucoma."

The results indicate that an individualized assessment of the risk of developing glaucoma can aid patients and clinicians in making treatment decisions. "Clinicians need to consider the patient's age, health status, life expectancy and personal preferences when making such decisions. Ultimately, the full extent of the penalty for delaying treatment will require longer follow-up to ascertain the incidence and degree of visual impairment by randomization group," the authors conclude.

Editorial: Treatment Decisions Remain in the Hands of Clinicians and Patients

The study design attempts to answer the perennial question of whether patients with ocular hypertension should receive pressure-lowering medications, writes Alfred Sommer, M.D., M.H.S., of Bloomberg School of Public Health, Johns Hopkins University, Baltimore, in an accompanying editorial.

"The new Ocular Hypertension Treatment Study data throw interesting light on the issue, though the answer probably remains unchanged: 'It all depends,'" Dr. Sommer writes. "The thoughtful clinical decision depends on whether treating the patient might do more harm than good."

"In the end, the physician is stuck with the persistent problem of whom to treat and whom to watch," they write. "The fascinating article by Kass et al provides interesting insights as to many of the issues at stake, but offers little definitive information to guide us. It probably still makes sense that young patients with lots of high risk factors should receive prophylaxis [preventive therapy], while elderly patients with few risk factors should not. The endless symposia and debates on how best to manage patients with ocular hypertension will probably continue unabated."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Michael A. Kass; Mae O. Gordon; Feng Gao; Dale K. Heuer; Eve J. Higginbotham; Chris A. Johnson; John K. Keltner; J. Philip Miller; Richard K. Parrish; M. Roy Wilson; for the Ocular Hypertension Treatment Study Group. Delaying Treatment of Ocular Hypertension: The Ocular Hypertension Treatment Study. Arch Ophthalmol, 2010; 128 (3): 276-287 [link]
  2. Alfred Sommer. Treatment of Ocular Hypertension: Hamlet's Lament Revisited. Arch Ophthalmol, 2010; 128 (3): 363-364 [link]

Cite This Page:

JAMA and Archives Journals. "Study examines effects of delaying treatment for ocular hypertension." ScienceDaily. ScienceDaily, 8 March 2010. <www.sciencedaily.com/releases/2010/03/100308171145.htm>.
JAMA and Archives Journals. (2010, March 8). Study examines effects of delaying treatment for ocular hypertension. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/2010/03/100308171145.htm
JAMA and Archives Journals. "Study examines effects of delaying treatment for ocular hypertension." ScienceDaily. www.sciencedaily.com/releases/2010/03/100308171145.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins